SLC5A2 and hydrops fetalis: Results from a recent meta-analysis also demonstrated the time-varying effects of SGLT2 inhibitors, in that reduction in endpoints such as HF hospitalization and all-cause mortality were greatest within 3 months of initiating therapy [110].